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Studies on sulfate in end-stage renal disease. The sparsely stud-
ied matter of sulfate retention in end-stage renal disease was un-
dertaken at our institution in recognition of the fact that the sor-
bent cartridge system of hemodialysis (SCD) used with our home
dialysis patients does not remove sulfate as does the single pass
system (SPD) used with many of our center patients. The find-
ings were as follows: (1) In nondialyzed patients, serum sulfate
(S2) was positively correlated with serum creatinine (Scr); hy-
persulfatemia was generally present when the Scr exceeded 2 mg/
100 ml. (2) In the dialysis patient, urinary volume and urinary
sulfate excretion were positively correlated. (3) The sorbent car-
tridge did not adsorb sulfate from the dialysate to an appreciable
degree. (4) In SPD patients, the Ss0 decreased from 2.60 to 0.89
mmoles/liter, a decrement of 66%. In contrast, in SCD patients
receiving a comparable duration of hemodialysis, the Ss0 de-
creased from 3.62 to 2.87 mmoles/liter, a decrement of only 22%.
(5) Twenty-nine home dialysis patients treated with SCD when
seen in renal clinic had a mean Ss0 of 4.41 mmoles/liter com-
pared to a S20value of 2.07 mmoles/liter in 23 center dialysis
patients (SPD) also seen in the renal clinic. The patients were
otherwise comparable in terms of age, duration of dialysis, Sr,
total C02, and serum phosphorus. The alkaline phosphatase was
significantly higher in home dialysis patients. (6) In previously
undialyzed patients, the predialysis SSO increased over several
weeks in some but not all the patients after the initiation of SCD;
this rise did not occur in patients treated with SPD. We conclude
that sorbent cartridge hemodialysis promotes high serum sulfate
levels in many dialysis patients, especially those with less residu-
al renal function.
Etude du sulfate dans l'insufllsance rénale terminale. L'étude
de la retention de sulfate dans l'insuffisance rénale terminale a
été entreprise dans notre institution quand il a été connu que le
système d'hémodialyse a cartouche d'absorbant (SCD) utilisé
pour nos malades en hemodialyse a domicile ne soustrait pas le
sulfate a La difference du système a passage unique (SPD) em-
ployé pour les malades traités au centre. Les constatations ont
été les suivantes: (1) Chez les malades non dialyses La concentra-
tion sérique de sulfate (S50) est positivement correlèe a Ia con-
centration sérique de crèatinine (Scr); l'hypersulfatemie existe
gdnéralement quand S. dèpasse 2 mg/l00 ml. (2) Chez les mal-
ades dialyses Ic debit urinaire et l'excrétion urinaire de sulfate
sont positivement correlés. (3) La cartouche d'absorbant ne
soustrait pas sulfate du dialysat de facon appreciable. 4) Chez
les malades en dialyse SPD S0 diminue de 2,60 a 0,89 mmoles/
litre, une diminution de 66%. Au contraire, au cours de
l'hemodialyse SCD de durée comparable S0 diminue de 3,62 a
2,87 mmoles/litre, une diminution de 22% seulement. (5) Vingt
neuf malades en hémodialyse a domicile traités par SCD avaient
un S0 moyen de 4,41 mmoles/litre au lieu de 2,07 mmoles/litre
chez 23 malades traités au centre par SPD. Les malades ètaient
d'autre part comparables en ce qui concerne l'âge, Ia durée de la
dialyse, Sr, le CO2 total, Ic phosphore sérique. La phosphatase
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alcaline était significativement supérieure chez les malades en
dialyse a domicile. 6) Chez les malades non dialyses an-
térieurement le Sso predialytique a augmentè pendant plusieurs
semaines chez certains, mais non tous, après le debut de SCD;
cette augmentation n'a pas èté observée chez les malades traités
par SPD. Nous concluons que l'hemodialyse avec cartouche
d'absorbant determine des concentrations sériques de sulfate é-
levees chez ces malades en dialyse chronique, particulièrement
ceux qui ont Le moms de fonction rénale résiduelle.
Sulfate retention as a consequence of renal failure
has been known for many years [1-3]. In the non-
dialysis population with renal disease, serum sulfate
concentration is correlated positively with both
blood urea nitrogen (BUN) and serum phosphate
concentrations [4]; the increased concentration of
serum sulfate is presumably a consequence of de-
creased renal excretion of sulfate together with con-
tinued ingestion of sulfur-containing foodstuffs.
The dialyzability of sulfate was demonstrated by
Holmes, Miller, and Hlad in a group of patients with
both acute and chronic renal failure [5]. Because of
the many similarities between the renal handling of
phosphate and sulfate, increased serum sulfate is an
anticipated finding in patients receiving long-term
maintenance dialysis. The pathologic significance of
sulfate retention, if any, is unknown.
For the past 3 years, we have used the sorbent
cartridge dialysis system (REDY machine as manu-
factured by CCI Life Systems, Inc.) [6] for the
treatment of most of our home dialysis patients.
The cartridge as presently manufactured (July,
1978) is not specifically designed to remove sulfate.
We therefore studied sulfate metabolism in patients
with end-stage renal disease treated with either sor-
bent cartridge dialysis or standard single-pass dial-
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ysis to determine specifically: (I) the mechanisms
and magnitude of difference in sulfate removal be-
tween the two systems; (2) whether differences in
other blood chemistry determinations in addition to
sulfate could be found; (3) the influence of residual
urinary excretion of sulfate on serum sulfate con-
centration; (4) the stability of the concentration of
serum sulfate in patients one month from the next;
(5) the influence of long-term hemodialysis of either
type on serum sulfate concentration.
Methods
Two main categories of our renal clinic patients
were studied: hemodialysis patients and nondialysis
patients with renal disease of various causes and
with varying severity. The dialysis patients were
treated either with conventional single-pass hemo-
dialysis or with sorbent cartridge hemodialysis. All
patients were studied with informed consent. The
specific objectives and methods of study are listed
below.
Patient studies: (1) Normal values. Serum sam-
ples were obtained from 30 patients with uncompli-
cated essential hypertension. These patients were
subjects of a separate protocol in which complete
medical history, physical examination, chest radio-
graph, electrocardiogram, urinalysis, and creatinine
clearance were performed. The mean age was 40
years (± 1.5 SEM), and the mean serum creatinine
concentration was 1.0 mgIlOO ml (±0.03 SEM). That
patients with uncomplicated hypertension have nor-
mal serum sulfate values has previously been docu-
mented [31.
(2) The relationship of serum sulfate to renal
function in nondialysis patients. The concentrations
of serum sulfate were measured in 40 patients with
renal disease whose serum creatinine concentra-
tions ranged from 0.6 to 16.8 mg/100 ml. None of
these patients was receiving hemodialysis. The pa-
tients' blood samples were taken at the time of regu-
larly scheduled renal clinic appointments.
(3) The effect of a single dialysis on serum sul-
fate. Pre- and postdialysis blood samples were ob-
tained on eight patients treated with single-pass
dialysis (Cobe Centry Delivery System) and were
compared to eight patients treated with sorbent car-
tridge dialysis. Gambro 13.5-p dialyzers were used,
and all patients were dialyzed for 6 hours.
(4) Clearances of plasma sulfate: Sorbent car-
tridge dialysis vs. single pass dialysis. In six dial-
ysis patients (three receiving sorbent cartridge dial-
ysis and three receiving single-pass dialysis), clear-
ances of plasma sulfate by the dialyzers were
studied at the beginning and end of a regularly
scheduled hemodialysis. The first samples were ob-
tained 10 mm after the initiation of hemodialysis,
whereas the samples at the end of the dialysis were
obtained during the 4th or 5th hours. The blood flow
rate as determined by the bubble-timing method
was 250 mllmin in all instances. Clearances were
calculated by dividing the differences in plasma sul-
fate between the inlet and outlet of the dialyzer by
the plasma sulfate in the inlet and multiplying by the
blood flow rate.
(5) Stability of serum sulfate. Predialysis serum
samples were obtained in 14 center dialysis patients
on two occasions separated by one month; the cor-
relation coefficient between the two samples was
measured.
(6) Comparison of serum sulfate and other vari-
ables: Sorbent cartridge vs. single-pass dialysis.
From 29 home dialysis patients receiving sorbent
cartridge dialysis, serum samples were obtained at
the time of normally scheduled clinic visits. These
interdialytic sulfate values were compared to those
of 23 patients treated with the standard dialysate de-
livery systems at satellite dialysis units also seen at
the renal clinic during the same time interval; these
two groups were also compared from the standpoint
of age, sex, duration of dialysis, serum creatinine,
phosphorus, urea nitrogen, and total CO2. A retro-
spective analysis of alkaline phosphatase data ob-
tained during the visits was also made. Those pa-
tients known to have active renal osteodystrophy
before the initiation of hemodialysis therapy were
excluded from this analysis.
(7) Influence of long-term dialysis on serum sul-
fate: Sorbent cartridge vs. single-pass dialysis. Sev-
eral patients have been studied sequentially from
the initiation of hemodialysis. Their serum sulfate
concentrations were determined at 2-week intervals
for 3 months and thereafter every 3 months. Pa-
tients treated with sorbent cartridge dialysis, as well
as standard single pass dialysis, have been studied.
Whenever possible, simultaneous arterial pH and
Pco2 were monitored, and the bicarbonate was cal-
culated. In patients dialyzing in the center and
home-training units, blood samples were obtained
immediately before each dialysis. Once patients
were discharged to home for dialysis, samples were
obtained on an interdialytic basis.
(8) Urinary sulfate excretion in renal disease. In
55 patients with renal disease of different causes,
24-hour urine collections and serum samples were
obtained at the same renal clinic visit for the mea-
surement of sulfate and creatinine. The patients
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Table 1. Serum and urine sulfate recovery
Expected value Observed value
mM/liter mM/liter % Recovery
A. Recovery determination on serum sulfate
Patient I
Pooled serum A — 1.59 —
1/2ccA + 1/2 cc 0.5 ifiM Std 1.05 1.14 109
1/2cc A + 1/2 cc 1.0mM Std 1.30 1.35 103
1/2ccA + 1/2cc2.OmMStd 1.80 1.85 103
1/2cc A + 1/2cc 2.5 mi Std 2.05 2.07 101
Patient 2
PooledserumB — 1.00 —
1/2cc B + 1/2cc 0.5 mrvi Std 0.75 0.74 97
1/2ccB + 1/2ccl.OmMStd 1.00 1.01 101
1/2ccB + 1/2cc2.OmMStd 1.50 1.53 102
1/2cc B + 1/2cc 2.5 mai Std 1.75 1.78 102
Patient 3
Pooled serum C — 0.83
1/2 ccC + 1/2cc 0.5 mai Std 0.67 0.69 103
l/2ccC + 1/2ccl.OmMStd 0.92 0.94 102
1/2ccC + 1/2cc2.OmMStd 1.42 1.46 103
1/2 ccC + 1/2cc 2.5 mai Std 1.67 1.70 102
B. Method of additions on urines for sulfate
Patient 4 1.24 1.19 96
1.39 1.38 99
1.64 1.65 101
2.14 2.13 100
2.39 2.41 101
2.64 2.69 102
Patient5 — 0.52 —
0.36 0.37 103
0.51 0.54 106
0.76 0.79 104
1.26 1.30 103
1.51 1.50 99
1.76 1.75 99
Patjent6 — 1.61 —
0.91 0.92 101
1.06 1.06 100
1.31 1.22 93
1.81 1.75 97
2.06 2.01 98
2.31 2.27 98
C. Influence of phosphorus on inorganic sulfate
l/2ccSO4Std + 1/2cc 1 mg/lOOmlPO4Std 1.50 1.50 100
1/2ccSO4Std + 1/2cc3mg/100mlPO4Std 1.50 1.48 99
1/2 cc SO4 Std + 1/2ccsmg/lOOmlPO4Std 1.50 1.52 101
1/2ccSO4Std + 1/2cc7mg/lOOmlPO4Std 1.50 1.52 101
1/2ccSO4Std + 1/2cc IOmg/IOOmlPO4Std 1.50 1.53 102
D. Heparin influence on inorganic sulfate
Pooled sera (0.05 cc H20 added/Icc sera) — 3.06
lccsera + Icc 0.2 mi SO4 Std 1.63 1.80 110
I ccsera + Icc 0.5 mi SO4 Std 1.78 1.87 105
lccsera+ Icc I.OmMSO4Std 2.03 2.11 104
lccsera+lcc2.OmMSO4Std 2.53 2.62 104
Pooled sera (0.05 cc H2O added/Icc sera) — 3.04 —
1 ccHepsera + I cc 0.2 m SO4 Std 1.62 1.78 110
I ccHepsera + Icc 0.5 mrt SO4 Std 1.77 1.94 110
I cc Hep sera + Icc 1.0mM SO4 Std 2.02 2.15 106
lccHepsera+ lcc2.OmMSO4Std 2.52 2.65 105
Coefficient of vanation in known samples
No. of
determinations Mean SD % Coefficient variation
Labtrol pool 47 13.63 0.39 2.9
Rat plasma pool 48 0.92 0.04 4.3
Human plasma pool 24 0.56 0.05 8.9
Human plasma pool 10 2.07 0.08 3.9
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were subsequently divided into three groups on the
basis of renal function: group 1, serum creatinine
concentrations less than 1.4 mg/l00 ml; group 2,
creatinine concentrations of 1.7 to 9.9 mgIlOO ml;
group 3, dialysis patients. Of the 24 patients in
group 3, 22 were receiving sorbent cartridge dialysis
at the time of sampling.
(9) Sorbent cartridge handling of sulfate. The
sulfate content of dialysate entering and leaving the
sorbent cartridge was analyzed at 5-mm intervals
during the first hour of three patient dialyses and
then hourly during the remaining 5 hours of four pa-
tient dialyses. The result of each sampling time was
expressed as the ratio of the effluent dialysate sul-
fate concentration to the affluent concentration. A
ratio less than 1 represents removal of dialysate sul-
fate by the cartridge, a ratio greater than I repre-
sents release of sulfate into the dialysate, and a ratio
of 1 represents an equilibrium between cartridge
and dialysate.
Sampling and chemical methods. Blood obtained
for sulfate was centrifuged as soon as possible, and
the serum was extracted and frozen for determina-
tion at a later time.
Inorganic serum sulfate concentration was mea-
sured by the turbidmetric method of Bergiund and
Sorbo [71, modified for autoanalyzer use by Hass
[8]. In this method, barium (added as barium chlo-
ride) forms a precipitate with the inorganic sulfate
in the sample; the precipitate is held in suspension
by gelatin to allow turbidimetric measurement at
420 m. Baseline drift, lack of sensitivity, and precip-
itate coating of coils and tubing are potential prob-
lems. Maximal sensitivity has been obtained by us-
ing a 1:1 mixture of commercial grade (Knox brand)
5,
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Fig. 1.Relationship of the serum sulfate to serum creatinine con-
centrations in 40 patients with renal disease.
and microbiologic grade (Difco brand) gelatin. The
barium-gelatin reagent is prepared 72 hours before
use and is aged during this interval; it then must be
used within 24 to 48 hours. All other reagents are
•
• prepared on the day of the test. Glass coils on the
: • manifold, dialyzer plates, dialyzer coils, and flow-
through cuvettes must be checked before each run
* • and frequently require cleaning. The glass coil in
the 37° C heating bath should be cleaned every four
to six runs with 5 to 10 N sodium hydroxide.
Since even under ideal conditions there will be
some baseline drift, we routinely have run our sam-
ples in groups of ten bracketed by standard curves.
Each sample is then read from two standard curves,
and the two results are averaged. Standard recov-
ery experiments on both serum and urine have giv-
en excellent results (Table 1). Four different control
samples have been used to check the variation of
the method. The coefficient of variation in these
samples appears in Table 1.
Although this method, as originally described by
Berglund and Sorbo, was stated not to be influ-
enced by the phosphate content of blood, phos-
phate in the range of Ito 10 mg/l00 ml was added to
a sulfate standard to further rule out this possibility.
No influence of phosphate on the sulfate determina-
tion was noted (Table 1).
Finally, it has been stated that heparinized
plasma cannot be used in the measurement of sul-
fate by this method [8]. Since our post dialysis sam-
ples are unavoidably heparinized to some degree,
6
Predialysis Postdialysis
4
2
S Sorbent cartridge
dialysis
0Single-pass
dialysis
S
E
5-
Fig. 2. Predialysis and postdialysis plasma sufate resulting from
one sorbent cartridge or single-pass hemodialysis in each of
16 patients.
0
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we tested the influence of heparin on the determina-
tion. We used the method of additions on a serum
sample which we split. Half of the sample received
diluted heparin, and the other half received a com-
parable volume of deionized water per cubic cen-
timeter of serum. The final concentration of heparin
in the first aliquot was 0.5 U/cc of serum. Blood was
also drawn from another individual; the first part of
the specimen was allowed to clot, whereas the sec-
ond part was placed in a tube containing 100 U of
heparin (Table 1). Fairly low amounts (0.5 U/ml) of
heparin were used in the first test using the method
of additions. A much higher concentration (100 U/
ml) was used in the second test. In neither case did
the heparin seem to affect the final inorganic sulfate
results.
An autoanalyzer technique (Technicon) was used
to determine the serum urea nitrogen concentration
after a modification of the carbamido-diacetyl reac-
tion, the serum creatinine concentration after a
modification of the Folin and Wu method, the in-
organic phosphorus concentration after a modifica-
tion of the Fiske and Subbarow procedure, the alka-
line phosphatase activity after a modification of the
Bessey, Lowry and Brock method, and the total
serum CO2 value by a colorimetric technique.
Inlet Pso Outlet Pso, Cs0
Single-pass dialysis mmoles/liter mi/mm
Patient 1
10mm 0.88** 053 994
4 hr 0.43 0.27 93.0
Patient 2
10mm 1.90 0.98 121.1
4hr 0.82 0.37 137.2
Patient 3
10mm 1.71 0.86 124.3
4hr 0.95 0.57 100.0
Sorbent cartridge dialysis
Patient I
10mm 1.48 1.13 59.1
Shr 1.35 1.37
Patient 2
10mm 2.46 1.58 89.4
Shr 2.19 2.15
Patient 3
10mm 3.46 2.36 79.5
Shr 2.70 2.69
We used Gambro 13.5-p dialyzers at a blood flow rate of 250
mI/mm, and a dialysate flow rate of 500 mI/mm for single-pass
and 200 mL'min for sorbent cartridge dialysis.
Results
The mean serum sulfate concentration in 30 con-
trol subjects was 0.39 mmole/liter 0.1 SEM. This
value is comparable to normal values established by
Hanze [4] and Loeb and Benedict [2].
Figure 1 shows the relationship of serum sulfate
to the serum creatinine concentrations in 40 pa-
tients with renal disease of diverse etiology. A cor-
relation coefficient of 0.80 (P < 0.01) was calcu-
lated; the serum sulfate concentration was generally
increased if the serum creatinine concentration ex-
ceeded 2 mg/100 ml.
In single-pass dialysis patients (Fig. 2), the serum
sulfate concentration decreased from 2.60 0.30
(predialysis) to 0.89 0.10 mmole/liter (post-
dialysis), a decrement of 66%. In contrast, with pa-
tients receiving a comparable duration of hemo-
dialysis with the sorbent cartridge dialysis, the
serum sulfate concentration decreased from 3.62 to
2.87 mmoles/liter, a decrement of only 22%.
Results of clearances of sulfate appear in Table 2.
In the single-pass dialysis patients, sulfate clear-
ance ranged from 93 to 137 mllmin; there appeared
to be no appreciable difference in sulfate clearance
when comparing early to late dialysis. With the sor-
bent cartridge dialysis patients, the sulfate clear-
ance 10 mm after the initiation of dialysis ranged
from 59 to 89 mllmin. There was essentially no evi-
dence that sulfate was being cleared at the end of a
dialysis procedure in these patients, however.
Figure 3 compares the predialysis serum sulfate
concentrations in 14 stable patients treated with
single-pass dialysis from one month to the next. The
correlation coefficient was high (r = 0.90, P <
4.0
.
3.O • S
2.0
E r=0.90
2 $
.
P<0.001
0'f/ I0 1.5 2.5 3.5 4.5
Serum sulfate, mmoles/Iiter
(April 1977)
Fig. 3. Predialysis serum sulfate concentrations in 14 single-pass
hemodialysis patients during 2 consecutive months.
Table 2. Sulfate clearances in sorbent cartridge and single-pass
dialysis patientsa
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Table 3. A comparison of single-pass and sorbent cartridge dialysis patients
Single-pass dialysis Sorbent cartridge dialysis P value
No. of patients 23 29
Age,yr 46 4 49 2 NS
Duration dialysis, months 28 4 25 3 NS
Serumcreatinine,mg/lOOml 13.1 0.9 12.4 0.6 NS
Serum urea nitrogen, mg/100 ml 66 4 66 4 NS
SerumPO4,mgIJOOmI 5.0 0.4 5.4 0.3 NS
Serum S04,mmoles/Iiter 2.07 0.13 4.41 0.23 <0.001
Serum C02,mmoleslliter 21 0.7 22 0.6 NS
Serum alkaline phosphatase,IU/liter 121 13 (N = 17) 212 34 (N = 20) <0.05
Time, weeks
B
4-
3-
2
c I0 5 10 15 20 25 30
Time, weeks
Fig. 4. Serum sulfate concentrations in five patients on sorbent
cartridge (A) and four patients on single pass (B) hemodialysis
over time.
0.00 1), indicating little fluctuation with single-pass
dialysis.
In Table 3, home dialysis patients are compared
to center dialysis patients from the standpoint of
age, duration of dialysis, serum creatinine, BUN,
0
Co
h
Co
0
0
E .
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serum sulfate, total C02, serum phosphate, and al-
kaline phosphatase. Although the serum sulfate was
more than twice as high in sorbent cartridge dialysis
patients, all other factors analyzed were compar-
able except the alkaline phosphatase activity, which
was significantly higher in the sorbent dialysis
group.
A Figure 4 depicts the concentrations of serum sul-
fate over time in five patients on sorbent cartridge
dialysis compared to four on single-pass dialysis.
The figure illustrates two points: (1) during the ini-
tial 12 to 16 weeks of dialysis, the serum sulfate
concentration with single-pass dialysis appears sta-
ble, whereas the serum sulfate concentration with
sorbent cartridge dialysis tends to rise to a higher
concentration; (2) not all patients on sorbent car-
tridge dialysis display this pattern; three of the five
patients show stable concentrations comparable to
that of the single-pass dialysis patients. The creati-
nine clearances were 0.5 and 2 mllmin in the pa-
tients whose serum sulfate concentrations in-
creased and were 2, 4, and 6 mllmin in the three
patients whose serum sulfate stabilized at lower
concentrations.
One hundred and two blood gas and electrolyte
samples were obtained from 13 patients receiving
sorbent dialysis for an average of 8.5 weeks (range,
6 to 11 weeks). There was a significant positive cor-
relation between the serum sulfate and the anion
gap [SNa — (S1 + S03)] (r = 0.643, P < 0.001).
Neither the serum sulfate nor the anion gap corre-
lated significantly with the blood pH, Pco2 or calcu-
lated serum bicarbonate. The average anion gap
was 19 4 mEq!liter, and the average serum sulfate
concentration was 2.82 1.20 mmoles/liter. The
serum sulfate represented 29.5% of the anion gap.
In 32 samples from seven patients receiving single-
pass dialysis, the mean predialysis pH was 7.38 in
contrast to a value of 7.42 in 54 samples on 10 pa-
tients receiving sorbent cartridge dialysis.
Table 4 depicts the mean serum creatinine con-
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Table4. Influence of renal function on serum and urinary sulfatea
Group 1
(serum creatinine
<1.4 mg/100 ml)
Group 2
(serum creatinine
1.7-9.9 mg/100 ml)
Group 3
(hemodialysis patients)
No. of patients 15 16 24
Serumcreatinine,mg/lOOml 1.0 0.6 4.3 0.6C 10.3 0.27e
Serumsulfate,mmoleslliter 0.44 0.02 1.07 0.10e 3.16 0.27e
Urinevolume,mlI24hr 1790 216 2016 224(NS) 777 126e
Urine sulfate,mmolesl24 hr 23.9 3.3 15.7 19b 9.5 I.1
Creatinineclearance,ml/min 116 14 25 4' 3 ie
a All values are mean 5EM.
P < 0.05 (group 1 vs. group 2).
P < 0.001 (group 1 vs. group 2).
p <0.01 (group 2 vs. group 3).
ep < 0.001 (group 2 vs. group 3).
centration, creatinine clearance, serum sulfate con-
centration, 24-hour urine volume and urinary sul-
fate excretion in three groups of subjects based on
their levels of renal function: group 1 (serum creati-
nine less than 1.4 mg/l00 ml), group 2 (serum creati-
nine of 1.7-9.9 mg/100 ml), and group 3 (hemo-
dialysis patients). The three groups are significantly
different according to both serum creatinine con-
centrations and creatinine clearances.
Urinary sulfate excretion diminished significantly
(group 1, 23.9 3.3 mmoles/24 hours; group 2, 15.7
1.9; and group 3, 9.5 1.1) as renal function de-
clined. The correlation coefficients of urinary sul-
fate excretion versus creatinine clearance was sig-
nificant (r = 0.77) at the 1% level. The urinary vol-
ume was not different between groups 1(1790 216
ml!24 hr) and 2 (2016 224 m1124 hr). The urinary
volume of the dialysis patients, however, was sig-
nificantly lower. Considering all three groups to-
gether, the 24-hour urinary sulfate excretion corre-
lated significantly with the urine volume (r = 0.62, P
< 0.01). The serum sulfate concentration rose sig-
nificantly (group 1, 0.44 0.02 mmole!liter; group
2, 1.07 0.10 and group 3, 3.16 0.27) as urinary
sulfate excretion declined (correlation coefficient of
serum versus urinary sulfate for all three groups
combined = 0.53, P < 0.01). In addition, the serum
sulfate concentration correlated significantly with
the serum creatinine (r = 0.78, P < 0.01). This was
comparable to the correlation observed in a similar
group of patients (Fig. 1). Residual function even in
the dialysis patient does influence serum sulfate
concentration. In the 24 patients in group 3 (receiv-
ing hemodialysis) correlation coefficient between
serum sulfate and creatinine clearance showed an r
value of 0.75 (P <0.001); the correlation coefficient
between the serum sulfate and urinary volume in
these patients showed an r value equal to 0.57 (P <
0.01).
Figure 5 illustrates the handling of dialysate sul-
fate by the sorbent cartridge. Sulfate was removed
from the dialysate during the initial 15 mm of dial-
ysis, indicated by the cartridge sulfate effluent/af-
fluent ratio less than 1. It was then released from the
cartridge during the next 20 mm, after which the
cartridge and the dialysate remained in equilibrium
during 6 hours of dialysis. Thus, the cartridge did
not adsorb sulfate from the dialysate to an appre-
ciable degree.
Discussion
Knowledge of the sulfate handling in renal failure
has been summarized well by Schreiner and Maher
[9] in their monograph published in 1961; relatively
0
C0
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'0
0
>.
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Time, rn/fl
Fig. 5. Dialysate sulfate adsorption pattern of the D-31 sorbent
cartridge during the first hour of hemodialysis of three patients.
EIA denotes effluent-to-affluent.
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little on this subject has been written since that time
with the exception of the paper already cited [4].
Sulfate exists in the blood in an organic and an in-
organic form. The inorganic sulfate is confined to
the extracellular space and has a normal concentra-
tion of approximately 0.39 mM/liter. Urinary sulfate
is normally slightly less than 1 g/day. In renal dis-
ease, the serum sulfate concentration rises in pro-
portion to the degree of azotemia, the highest levels
being seen in acute renal failure.
It is unlikely that the retention of inorganic sul-
fate produces acute toxicity, although there are lim-
ited studies regarding this point. First of all, the use
of radiolabeled sulfate has been administered for
many years under many experimental designs with-
out any toxicity being noted. Second, patients with
acute renal failure tend to have the highest serum
sulfate concentrations, and thus far no acute toxic
effects have been noted regarding sulfate retention
in this circumstance. The influence of chronically
elevated serum sulfate on the clinical state has not
been rigorously studied as far as we know.
Little is known about sulfate handling in hemo-
dialysis patients; therefore, its importance has not
been established in the treatment of chronic renal
failure. Although a distinct decrement in serum sul-
fate occurs during the single-pass hemodialysis, the
postdialysis sulfate values are not normal, and the
subsequent predialysis sulfate values are four to
five times greater than they are in patients with nor-
mal renal function. Whereas no harmful effects
from this degree of hypersulfatemia have been re-
ported, no specific studies directed to this problem
are available. The sorbent system of hemodialysis,
since it does not remove sulfate to an appreciable
degree, might bring to light effects of hyper-
sulfatemia not apparent at levels seen with single-
pass systems. It is important to understand in com-
paring the effects of the two dialysis systems that
the issue is not the effects of an abnormal serum
sulfate versus a normal serum sulfate concentra-
tion. Instead, it is one of a greater abnormality (sor-
bent dialysis) versus a lesser abnormality (single-
pass dialysis), both of which are substantially above
the normal serum concentration seen with un-
impaired renal function.
The measurement of sulfate by the turbidimetric
method of Sorbo and Bergiund [7] and modified for
autoanalyzer use by Haff [8] is both precise and ac-
curate. Phosphate does not interfere with this meth-
od. Furthermore, heparin at concentrations used
during hemodialysis has no influence on serum sul-
fate concentration. The difficulties in the sinnular
use of either microbiologic grade (Difco) or com-
mercial grade (Knox) gelatin in the measurement of
sulfate have been described by Haff [81. We have
used therefore a 1:1 mixture of these gelatins. We
have learned also that the use of this reagent
beyond 48 hours leads to rapid baseline drift and
loss of sensitivity. Success of the method otherwise
depends upon the attention to cleanliness of coils
and cuvettes.
The rise in serum sulfate concentration is pre-
sumably influenced by a number of factors, includ-
ing dietary intake, gastrointestinal absorption, re-
sidual renal function, and for the patient with end-
stage renal disease receiving hemodialysis, the re-
moval of sulfate by dialysis.
Little is known about dietary sulfate and its in-
testinal absorption in renal disease. Differences in
dietary sulfate are unlikely to be responsible for the
differences in serum sulfate we have noted. Our pa-
tients have been instructed in diets containing 1 g of
protein per kilogram of body weight. Furthermore,
the serum urea nitrogen was comparable in each
group, indicating no major difference in protein in-
take. It should be emphasized, however, that diet-
ary sulfate was not controlled in this study.
Residual renal function appears to play an impor-
tant role in determining the concentration of serum
sulfate since the serum sulfate concentration corre-
lates significantly with the serum creatinine in two
samplings of clinic patients: one group of 40 not on
dialysis (Fig. 1) and another group of 55 with vary-
ing degrees of renal dysfunction, including those on
hemodialysis (Table 4). Even within the dialysis
population there is an inverse correlation between
serum sulfate and creatinine clearance and urinary
volume.
Sorbent cartridge differs from single-pass hemo-
dialysis in several ways. Instead of discarding the
dialysate after a single pass through the dialyzer,
the dialysate is recirculated through the dialyzer. A
sorbent cartridge is placed in the line of flow to re-
generate the dialysate, that is, to remove creatinine
and urea, before its return to the dialyzer. The sor-
bent system contains a 5.5-liter dialysate volume,
which increases during dialysis by the amount of
fluid ultrafiltered from the patient.
Providing that the sorbent cartridge completely
removes a given substance from the dialysate, the
sorbent cartridge system behaves like a single-pass
system. If a substance, however, is not removed by
the cartridge, that substance will increase in the
dialysate to a concentration equal to that of the pa-
tient's blood. A small amount of the substance will
Suifate in end-stage renal disease 175
be removed from the patient as his blood equili-
brates with the dialysate.
In the case of sulfate, it is apparent that the car-
tridge transiently removes only a small amount of
sulfate from the dialysate early in dialysis and then
promptly releases it (Fig. 5). This occurs within the
first 40 mm of dialysis, after which the patient is in
equilibrium with the sorbent system. It is clear from
Figure 2 that the sorbent system removes less sul-
fate from the patient than does the single-pass sys-
tem. This is the reason that the predialysis values of
the sorbent cartridge dialysis group are higher than
those of the single pass group are. The estimated
total amount of sulfate lost into the dialysate of
three patients after 6 hours of sorbent cartridge dial-
ysis, based on changes in serum sulfate, can be ac-
counted for by the measured gain of sulfate in the
dialysate.
It must be emphasized that due to the nature of
our hemodialysis program, the sorbent cartridge
group is composed entirely of home dialysis pa-
tients whereas the single-pass group is composed of
center dialysis patients. Though this could conceiv-
ably be responsible for some differences, the pa-
tients in both groups were similar from the stand-
point of age, sex, and duration of dialysis (Table 3)
and were dialyzed to the same degree as reflected
by the serum creatinine, blood urea nitrogen, and
phosphorus.
The serum sulfate concentrations of patients on
single pass hemodialysis were stable from one
month to the next as noted in Figs. 3 and 4. With
sorbent cartridge dialysis, however, the serum sul-
fate may take a number of months to stabilize. It is
apparent, however, from Figure 4 that the serum
sulfate concentrations of some patients on sorbent
cartridge dialysis display a pattern more like that of
the single pass patients. This is presumably due to
greater residual renal function observed in those
sorbent cartridge patients.
Despite a significant difference in serum sulfate
concentrations in patients on sorbent cartridge ver-
sus single-pass hemodialysis, the serum CO2 was
comparable. Within the sorbent cartridge group of
patients studied serially, there was no significant
correlation between the serum sulfate and the blood
pH, Pco9, or serum bicarbonate. In addition, there
was no significant correlation between the anion
gap and these same parameters. Thus, it appears
that, though the serum sulfate influences the mea-
surable anion gap, it does not correlate with the
state of acid balance. This may occur because the
hydrogen ion originally accompanying the sulfate
has been removed through dialysis by the sorbent
cartridge but the sulfate anion has not.
Whether the elevated serum sulfate concentra-
tions noted in both the sorbent cartridge and single-
pass groups have any pathologic significance is not
established. The home dialysis patients (sorbent
dialysis) are doing as well clinically as the center
patients are (single-pass dialysis). No evidence of
acute toxicity can be seen. We have, however, ob-
served another difference between these groups in
looking retrospectively at our data. The alkaline
phosphatase activity was higher in the sorbent car-
tridge than it was in the single-pass group. We are
presently more rigorously evaluating the alkaline
phosphatase values in these two types of patients.
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